Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by somweyungguyon Oct 05, 2016 9:59am
126 Views
Post# 25311091

RE:NO insider selling and "with this sample size"

RE:NO insider selling and "with this sample size"I don't understand why the phrase "with this sample size" was repeated twice in the recent news release.

The company and the FDA clearly stated the primary end point would be done on the final 176 patients, the last of the 446.  I do realize this number was extended to 180 as part of the eventual 450.

As much as we appreciate the 5% on "this sample size", what was the absolute benefit on the number of 176/180 as set by the FDA?

I have many questions and will reach out to the company for answers.

I've always known that games were being played here, they've become "downright dirty" and now our friends in the US have finally discovered the EDTXF ticker symbol and LONG or BUY button

Sqr
Read more at https://www.stockhouse.com/companies/bullboard#4PuA243kXuaexwMb.99
Bullboard Posts